Q-omics provides the consensus-scored TSLP profile across patient tissues and cancer cell-line models. TSLP expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TSLP is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, TSLP RNA expression shows 14,976 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, BLCA, and UVM as cancer lineages where TSLP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSLP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSLP survival associations across molecular data types. TSLP RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSLP RNA expression–survival associations across cancer types. High TSLP expression shows unfavorable associations in UVM, SCLC and LAML, but favorable associations in BRCA, LUSC and THYM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TSLP RNA expression.
This table summarizes TSLP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TSLP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSLP shows lower tumor expression in BLCA, KIRC, KICH, THCA, LUAD and LIHC. The BLCA box plot shows higher TSLP RNA expression in normal versus tumor tissue (log2 FC = −2.157, t-test p < 0.001).
This table shows molecular features associated with TSLP in patient tissues and cancer cell lines. In patient samples, TSLP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TSLP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
